文献速递浆细胞疾病

IRF2是多发性骨髓瘤中具有致病和预后影响的关键转录因子

IRF2 is an essential transcription factor with pathogenic and prognostic impact in multiple myeloma.
PubMed 文献 · Blood · 2026-01-01

该研究通过CRISPR-Cas9文库筛选在多发性骨髓瘤(MM)细胞中鉴定出22个关键转录因子,包括IRF2。IRF2广泛结合染色质,抑制坏死性凋亡并促进迁移,在MGUS和冒烟型MM中已有转录失调,高表达与更差的无进展生存和总生存相关,提示其作为治疗靶点的潜力。

要点

  • CRISPR-Cas9筛选揭示IRF2是MM细胞存活的关键转录因子。
  • IRF2高表达与MM患者更差的无进展生存和总生存相关。
  • IRF2在MGUS和冒烟型MM中已出现转录失调,参与早期疾病演变。

核心结论

  • IRF2是MM中未被充分认识的关键转录因子,参与疾病发病和临床行为,其抑制可失调关键信号通路,具有治疗靶点潜力。

研究设计与样本

  • 利用CRISPR-Cas9文库筛选在多发性骨髓瘤细胞中鉴定关键转录因子,并结合CUT&RUN染色质结合实验及临床预后分析。

主要发现

  • 在MM细胞中鉴定出22个关键转录因子,包括IRF家族成员,除已知IRF4外,IRF2为关键转录因子。
  • CUT&RUN显示IRF2广泛结合染色质,可独立或与IRF1、IRF4合作结合;IRF2独特区域主要关联活跃启动子,IRF2/1/4共结合区域偏向内含子。
  • IRF2通过抑制坏死性凋亡和促进细胞迁移贡献于MM细胞存活。
  • IRF2依赖的转录失调在MGUS和冒烟型MM等前驱状态中已明显,提示参与早期疾病演变。
  • IRF2高表达的MM患者无进展生存和总生存更差,单变量和多变量分析均显著,调整常见MM遗传风险因素后仍显著。

临床怎么用

  • IRF2表达水平可能作为MM预后评估的分子标志物,高表达提示更差的无进展生存和总生存。
  • IRF2抑制可失调MM发病关键信号通路,提示其作为潜在治疗靶点值得进一步开发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multiple myeloma (MM), the second most prevalent hematologic malignancy, remains incurable, highlighting the need to identify molecular drivers of disease progression and new therapies. Using a CRISPR-Cas9 library screening approach in MM cells, we identified 22 essential transcription factors (TFs), including members of the interferon regulatory factor (IRF) family. Remarkably, in addition to the well-known IRF4, IRF2 emerged as a critical TF in MM. Cleavage under targets and release using nuclease (CUT&RUN) experiments demonstrated that IRF2 binds extensively to chromatin, both independently and in cooperation with IRF1 and IRF4. Although IRF2-unique regions were predominantly associated with active promoters, regions bound by IRF2/1/4 were biased toward introns. Functionally, IRF2 contributes to MM cell survival by suppressing necroptosis and promoting cell migration. Notably, IRF2-dependent transcriptional dysregulation was evident in precursor conditions such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering MM (SMM), suggesting a role in early disease evolution. In addition to its role as an early factor, IRF2 levels also seem to influence disease progression, as MMs with higher expression demonstrated worse progression-free survival (PFS) and overall survival (OS) in both univariate and multivariate analyses, even after adjusting for common MM genetic risk factors. In conclusion, IRF2 constitutes an underappreciated essential TF involved in the pathogenesis and clinical behavior of MM. Its inhibition leads to dysregulation of key signaling pathways in MM pathogenesis, highlighting its potential as a therapeutic target.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Gómez-Echarte N, Carrasco-León A, Maiqués-Díaz A, et al. IRF2 is an essential transcription factor with pathogenic and prognostic impact in multiple myeloma. Blood. 2026. PMID: 42247308. doi:10.1182/blood.2025029422

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。